Assessment of metabolic syndrome parameters in pediatric acute lymphoblastic leukemia survivors

Indian J Cancer. 2023 Jul-Sep;60(3):325-330. doi: 10.4103/ijc.IJC_1110_20.

Abstract

Objective: This study aims to demonstrate the prevalence of metabolic syndrome parameters and to investigate their relationship with body mass index in pediatric acute lymphoblastic leukemia survivors.

Methods: The cross-sectional study was conducted between January and October 2019 at the Department of Pediatric Hematology and comprised acute lymphoblastic leukemia survivors who had been treated between 1995 and 2016 and had been off treatment for at least 2 years. The control group included 40 healthy participants who were matched for age and gender. The two groups were compared in terms of various parameters (BMI [body mass index], waist circumference, fasting plasma glucose, HOMA-IR [Homeostatic Model Assessment-Insulin Resistance], etc.). Data were analyzed using Statistical Package for the Social Sciences (SPSS) 21.

Results: Of the 96 participants, 56 (58.3%) were survivors and 40 (41.6%) were controls. Among the survivors, there were 36 (64.3%) men, whereas the control group had 23 (57.5%) men. The mean age of the survivors was 16.67 ± 3.41 years, whereas the mean age of the controls was 15.51 ± 4.2 years (P > 0.05). Multinomial logistic regression analysis showed that cranial radiation therapy and female gender were associated with overweight and obesity (P < 0.05). A significant positive correlation was found between BMI and fasting insulin, in survivors (P < 0.05).

Conclusion: Disorders of the metabolic parameter were found to be more common among acute lymphoblastic leukemia survivors than among healthy controls.

Keywords: Leukemia; metabolic syndrome; obesity; pediatric; survivors.

MeSH terms

  • Adolescent
  • Adult
  • Body Mass Index
  • Child
  • Cross-Sectional Studies
  • Female
  • Humans
  • Male
  • Metabolic Syndrome* / complications
  • Metabolic Syndrome* / epidemiology
  • Obesity
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
  • Survivors
  • Young Adult